Losartan Potassium Patent Expiration
Losartan Potassium was first introduced by Organon Llc A Sub Of Organon And Co
Losartan Potassium Patents
Given below is the list of patents protecting Losartan Potassium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Arbli | US11890273 | Losartan liquid formulations and methods of use | Oct 07, 2041 | Scienture |
| Arbli | US12156869 | Losartan liquid formulations and methods of use | Oct 07, 2041 | Scienture |
| Arbli | US12605365 | Losartan Liquid Formulations And Methods Of Use | Oct 07, 2041 | Scienture |
Losartan Potassium's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Losartan Potassium:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
| ||||
| Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer | University of Utah | NA |
COMPLETED
(Jul 1, 2026)
| PHASE1 |